BACKGROUND: Streptococcus pneumoniae is a major bacterial pathogens in acute otitis media. Pneumolysin is a species-specific protein toxin produced intracellularly by all clinically relevant pneumococcal strains, and antibodies to pneumolysin should therefore represent pneumococcal involvement in the disease, regardless of the serotype. METHODS: Antibodies to pneumococcal pneumolysin and capsular polysaccharides were measured by enzyme immunoassay in acute and convalescent sera of 121 children with acute otitis media. A pneumococcal otitis episode was defined by a positive middle ear fluid culture and/or pneumolysin PCR. RESULTS: Median age of the 10 children who developed a seroconversion response to pneumolysin was 1 year 8 months, and of the 21 children responding to polysaccharides it was 2 years 9 months. Eight of the 10 seroconversion responses to pneumolysin were of IgA class alone, whereas 17 of the 21 polysaccharide responses were of IgG class alone or IgG together with IgM and/or IgA. Of the 41 children with a pneumococcal otitis episode, 13 (39%) showed a seroconversion response, 3 (7%) to pneumolysin and 11 (27%) to capsular polysaccharides. The children with a pneumococcal otitis episode had lower titers of acute phase IgG to the capsular polysaccharide pool of S. pneumoniae (containing types 6B, 14, 19F and 23F), as compared with the titers in children with otitis caused by other pathogens and pneumococci only in the nasopharynx or not found at all (P = 0.04). CONCLUSIONS: Serum antibodies to pneumolysin can be detected at an earlier age than those to the capsular polysaccharides. However, a seroconversion is rare and therefore of no diagnostic value. The presence of serum IgG to the pneumococcal capsular polysaccharides seems beneficial in the prevention of pneumococcal otitis.
BACKGROUND:Streptococcus pneumoniae is a major bacterial pathogens in acute otitis media. Pneumolysin is a species-specific protein toxin produced intracellularly by all clinically relevant pneumococcal strains, and antibodies to pneumolysin should therefore represent pneumococcal involvement in the disease, regardless of the serotype. METHODS: Antibodies to pneumococcal pneumolysin and capsular polysaccharides were measured by enzyme immunoassay in acute and convalescent sera of 121 children with acute otitis media. A pneumococcal otitis episode was defined by a positive middle ear fluid culture and/or pneumolysin PCR. RESULTS: Median age of the 10 children who developed a seroconversion response to pneumolysin was 1 year 8 months, and of the 21 children responding to polysaccharides it was 2 years 9 months. Eight of the 10 seroconversion responses to pneumolysin were of IgA class alone, whereas 17 of the 21 polysaccharide responses were of IgG class alone or IgG together with IgM and/or IgA. Of the 41 children with a pneumococcal otitis episode, 13 (39%) showed a seroconversion response, 3 (7%) to pneumolysin and 11 (27%) to capsular polysaccharides. The children with a pneumococcal otitis episode had lower titers of acute phase IgG to the capsular polysaccharide pool of S. pneumoniae (containing types 6B, 14, 19F and 23F), as compared with the titers in children with otitis caused by other pathogens and pneumococci only in the nasopharynx or not found at all (P = 0.04). CONCLUSIONS: Serum antibodies to pneumolysin can be detected at an earlier age than those to the capsular polysaccharides. However, a seroconversion is rare and therefore of no diagnostic value. The presence of serum IgG to the pneumococcalcapsular polysaccharides seems beneficial in the prevention of pneumococcal otitis.
Authors: E Ling; G Feldman; M Portnoi; R Dagan; K Overweg; F Mulholland; V Chalifa-Caspi; J Wells; Y Mizrachi-Nebenzahl Journal: Clin Exp Immunol Date: 2004-11 Impact factor: 4.330
Authors: Michael E Pichichero; Ravinder Kaur; Janet R Casey; Albert Sabirov; M Nadeem Khan; Anthony Almudevar Journal: Vaccine Date: 2010-08-26 Impact factor: 3.641
Authors: Michael E Pichichero; Ravinder Kaur; Janet R Casey; Qingfu Xu; Anthony Almudevar; Martina Ochs Journal: Hum Vaccin Immunother Date: 2012-04-12 Impact factor: 3.452
Authors: S Lifshitz; R Dagan; M Shani-Sekler; N Grossman; G Fleminger; M Friger; Y Mizrachi Nebenzahl Journal: Clin Exp Immunol Date: 2002-02 Impact factor: 4.330
Authors: Catherine Laine; Tabitha Mwangi; Claudette M Thompson; Jacktone Obiero; Marc Lipsitch; J Anthony G Scott Journal: Infect Immun Date: 2004-06 Impact factor: 3.441
Authors: P Lehtinen; T Jartti; R Virkki; T Vuorinen; M Leinonen; V Peltola; A Ruohola; O Ruuskanen Journal: Eur J Clin Microbiol Infect Dis Date: 2006-07 Impact factor: 3.267